Dostarlimab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 256 publications
Tissue-Agnostic Cancer Therapy Approvals.
Journal: Hematology/oncology clinics of North America
Published: September 02, 2026
Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia.
Journal: Journal of medical economics
Published: July 31, 2026
Clinical Impact of Mismatch Repair Gene Mutation-Based Alert on Immunotherapy Decision Making Across Patients With Cancer.
Journal: JCO clinical cancer informatics
Published: July 27, 2026
Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis.
Journal: JCO precision oncology
Published: July 06, 2026
Envafolimab - novel anti-PD-1/PD-L1 antibody in cancer treatment.
Journal: Frontiers in immunology
Published: June 24, 2026
Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.
Journal: Journal of clinical medicine
Published: June 04, 2026
The Contribution of Dostarlimab to First-Line Treatment of Advanced or Recurrent Endometrial Cancer in Spain: A Multi-Criteria Decision Analysis Approach.
Journal: Journal of clinical medicine
Published: June 01, 2026
Immunotherapy-Induced Glutamic Acid Decarboxylase 65 Cerebellitis.
Journal: Cureus
Published: May 20, 2026
Systemic Treatment Strategies Beyond Chemotherapy in Recurrent or Advanced Endometrial Cancer: A Systematic Review and Meta-Analysis.
Journal: Cancers
Published: May 17, 2026
Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: May 05, 2026
Use, survival, and adverse events of dostarlimab monotherapy in advanced or recurrent endometrial cancer: a nationwide cohort study in France.
Journal: The oncologist
Published: April 24, 2026
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.
Journal: Science translational medicine
Published: April 22, 2026
Last Updated: 09/26/2026